Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.53 Insider Own1.86% Shs Outstand192.51M Perf Week0.61%
Market Cap157.86M Forward P/E- EPS next Y-0.71 Insider Trans-0.01% Shs Float188.94M Perf Month-5.75%
Income-100.69M PEG- EPS next Q-0.23 Inst Own17.79% Short Float0.28% Perf Quarter3.40%
Sales0.00M P/S- EPS this Y50.02% Inst Trans29.53% Short Ratio1.93 Perf Half Y-51.19%
Book/sh0.75 P/B1.09 EPS next Y-14.77% ROA-45.99% Short Interest0.54M Perf Year-43.45%
Cash/sh0.77 P/C1.06 EPS next 5Y21.22% ROE-56.56% 52W Range0.65 - 2.37 Perf YTD-13.94%
Dividend Est.- P/FCF- EPS past 5Y28.66% ROI-69.89% 52W High-65.40% Beta0.76
Dividend TTM- Quick Ratio5.38 Sales past 5Y0.00% Gross Margin- 52W Low26.15% ATR (14)0.05
Dividend Ex-Date- Current Ratio5.38 EPS Y/Y TTM1.77% Oper. Margin0.00% RSI (14)43.73 Volatility4.66% 5.74%
Employees85 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.57 Target Price3.82
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q5.87% Payout- Rel Volume0.32 Prev Close0.80
Sales Surprise85.23% EPS Surprise28.18% Sales Q/Q- EarningsOct 31 AMC Avg Volume277.02K Price0.82
SMA20-3.99% SMA50-7.09% SMA200-37.19% Trades Volume87,612 Change2.03%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
Feb-20-24 04:30PM
Jan-16-24 04:30PM
Dec-04-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 04:30PM
04:30PM Loading…
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Oct-27-23 04:30PM
Oct-16-23 02:00AM
Oct-05-23 04:30PM
Sep-05-23 04:30PM
Jul-31-23 04:25PM
Jul-25-23 04:30PM
Jul-19-23 04:30PM
Jul-10-23 04:30PM
04:30PM Loading…
Jun-16-23 04:30PM
Jun-08-23 04:30PM
Jun-06-23 05:00PM
May-10-23 05:30PM
May-09-23 04:30PM
May-04-23 04:30PM
Apr-19-23 05:09PM
Apr-12-23 04:30PM
Mar-24-23 04:30PM
Mar-13-23 01:30AM
Mar-07-23 04:30PM
Mar-02-23 05:30PM
Feb-27-23 01:30AM
Feb-21-23 04:30PM
04:30PM Loading…
Feb-10-23 04:30PM
Jan-23-23 04:30PM
Jan-04-23 04:30PM
Dec-23-22 01:30AM
Dec-08-22 04:30PM
Nov-22-22 04:30PM
Nov-09-22 01:30AM
Nov-03-22 04:30PM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Oct-03-22 04:30PM
Sep-21-22 05:45PM
Sep-07-22 04:30PM
Sep-02-22 04:30PM
Aug-10-22 04:50PM
Aug-01-22 04:30PM
Jul-27-22 04:30PM
Jul-20-22 04:30PM
Jun-28-22 06:15PM
Jun-16-22 01:30AM
Jun-09-22 02:55AM
Jun-07-22 04:30PM
May-17-22 04:30PM
May-12-22 04:30PM
May-04-22 07:30PM
May-02-22 05:00PM
Apr-25-22 07:30PM
Apr-21-22 04:30PM
Apr-14-22 04:30PM
Mar-14-22 04:30PM
Mar-11-22 04:30PM
Mar-09-22 04:30PM
Mar-03-22 04:15PM
Feb-24-22 04:30PM
Feb-22-22 04:30PM
Feb-14-22 04:30PM
Feb-09-22 04:30PM
Jan-21-22 04:30PM
Jan-18-22 05:38PM
Jan-12-22 04:30PM
Jan-07-22 01:30AM
Dec-20-21 04:15PM
Dec-10-21 04:30PM
Nov-24-21 01:30AM
Nov-04-21 04:30PM
Nov-01-21 03:34PM
Oct-29-21 05:07PM
Oct-27-21 03:35PM
Oct-26-21 04:15PM
Oct-12-21 04:30PM
Sep-08-21 04:00PM
Aug-31-21 01:30AM
Aug-20-21 04:15PM
Aug-09-21 04:30PM
Aug-06-21 04:30PM
Aug-02-21 04:15PM
Jul-26-21 04:30PM
Jul-07-21 04:30PM
Jun-15-21 04:30PM
Jun-02-21 01:30AM
May-19-21 04:30PM
May-17-21 04:30PM
May-05-21 05:00PM
May-03-21 01:30AM
Apr-29-21 01:30AM
Apr-28-21 04:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ndu AdoraDirectorFeb 06Buy0.891,8251,6241,825Feb 08 05:02 PM
Mohideen PharisChief Medical OfficerNov 22Sale1.742,2453,90682,194Dec 19 04:44 PM
MORRIS TIMOTHY EDirectorAug 25Buy1.5212,00018,24012,000Aug 28 04:35 PM
SOLAND DANIEL BDirectorAug 01Buy1.6215,00024,30020,000Aug 03 04:40 PM
Mohideen PharisChief Medical OfficerMay 24Sale3.544691,66049,439Aug 14 04:32 PM